Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Multicenter Open Label Prospective Study of Neoadjuvant Chemotherapy Docetaxel With or Without MEK Inhibitor SELUMETINIB in Patients With Early and Locally Advanced Triple Negative Breast Cancer

NCT02685657 is registered in ClinicalTrials.gov with Russian Academy of Medical Sciences as lead sponsor.

NCT NCT02685657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02685657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Multicenter Open Label Prospective Study of Neoadjuvant Chemotherapy Docetaxel With or Without MEK Inhibitor SELUMETINIB in Patients With Early and Locally Advanced Triple Negative Breast Cancer
Lead sponsor
Russian Academy of Medical Sciences
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2016
Completion date
Not reported
Enrollment
164 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer